Kura Oncology Inc KURA
News
Kura Oncology Reports Third Quarter 2026 Financial Results and Corporate Update
Kura Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Kura Oncology and Kyowa Kirin to Present First Ziftomenib-FLT3 Inhibitor Clinical Data at ASH 2026
Kura Oncology to Report Third Quarter Financial Results on November 10
Caspian Therapeutics and Kura Oncology Outline KO-7246 Development Strategy in Diabetes
Caspian Therapeutics and Kura Oncology to Host Investor Webcast Highlighting Caspian’s Launch and KO-7246 Preclinical Data in Diabetes
Kura Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Caspian Therapeutics Unveils KO-7246 at EASD as a Potential Best-In-Class Menin Inhibitor for Diabetes
Kura Oncology Launches Caspian Therapeutics with $50 Million Financing to Advance Menin Inhibition as a Potential Disease-Modifying Approach for Diabetes
Kura Oncology Appoints Jennifer Fulk as Chief Financial Officer
Kura Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Kura Oncology to Participate in Three Investor Conferences in September
